Icon Group launches COVID-19 home testing clinical trial for cancer patients

Cancer patients in Queensland, New South Wales and Victoria will now have the opportunity to further research into testing for COVID-19, following the launch of a clinical trial by Icon Group to assess the safety and feasibility of self-administered COVID-19 testing in the hopes of protecting immunocompromised patients and healthcare workers from active COVID-19 cases.

The clinical trial has launched at Icon Cancer Centre Wahroonga (NSW), South Brisbane (QLD), North Lakes (QLD), Wesley (Auchenflower, QLD) and Richmond (VIC) and will enrol a small number of new and current patients across a four week period, who will then perform a COVID-19 self-test at home prior to attending the centre for their next appointment.

With a strong history of cancer research, Icon Group now operates the largest private cancer clinical trials program in Australia and are proud to support patients and clinicians with access to clinical trials sponsored by the pharmaceutical industry, collaborative studies undertaken in partnership with universities or health focused organisations, and investigator initiated research sponsored by Icon Cancer Foundation.

Icon Group have been an active contributor in a number of milestone trials that have seen significant advancements in cancer treatments, including the ground-breaking trial that changed the use of Herceptin in breast cancer patients. This was also reflected in Icon Group’s recent TRANSFORM study, which found that stereotactic radiation therapy for metastatic prostate cancer can delay treatment progression for more than two years – changing the standard of care for men with advanced prostate cancer across the world.